评估西酞普兰、舍曲林、氟西汀和米氮平在长期维持抗抑郁药治疗初级保健患者中预防复发作用的随机对照试验(ANTLER:抗抑郁药预防抑郁复发):随机对照试验研究方案
ANTLER试验是一项个体随机、双盲、安慰剂对照试验,旨在评估英国初级保健中长期维持抗抑郁药治疗与安慰剂相比在预防抑郁复发方面的临床有效性和成本效果。研究对象为18至74岁、有至少两次抑郁发作、已服用抗抑郁药9个月或以上且目前服用西酞普兰20 mg、舍曲林100 mg、氟西汀20 mg或米氮平30 mg但状况良好可考虑停药者。参与者随机继续使用活性药物或服用相同安慰剂,经过2个月逐渐减量期,随访至52周,主要结局为随机化后至首次抑郁发作开始的时间(周)。
要点
- ANTLER试验评估长期维持抗抑郁药与安慰剂在初级保健中预防抑郁复发的有效性和成本效果。
- 纳入标准包括18-74岁、至少两次抑郁发作、服用抗抑郁药9个月以上且目前状况良好可考虑停药者。
- 主要结局为随机化后至首次抑郁发作开始的时间(周),采用回顾性版临床访谈量表修订版评估。
核心结论
- ANTLER试验 findings 将通过提供长期维持抗抑郁药治疗在英国初级保健中临床有效性和成本效果的有效且可推广的估计,为初级保健处方实践提供信息。
研究设计与样本
- ANTLER试验是一项个体随机、双盲、安慰剂对照试验,参与者随机继续使用活性药物或服用相同安慰剂,经过2个月逐渐减量期。
- 纳入标准:年龄18至74岁;有至少两次抑郁发作;已服用抗抑郁药9个月或以上,目前服用西酞普兰20 mg、舍曲林100 mg、氟西汀20 mg或米氮平30 mg,但状况良好可考虑停药。
- 随访时间为第6、12、26、39和52周。
关键数值与推荐
- 主要结局为随机化后至首次抑郁发作开始的时间(周),使用回顾性版临床访谈量表修订版在第12、26、39和52周进行测量。
- 次要结局包括抑郁和焦虑症状、不良反应、撤药症状、情绪加工任务、生活质量以及使用的资源和成本。
- 将基于试验结果进行成本效果分析。
临床怎么用
- ANTLER试验 findings 将通过提供长期维持抗抑郁药治疗在英国初级保健中临床有效性和成本效果的有效且可推广的估计,为初级保健处方实践提供信息。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antidepressants are used both for treating acute episodes and for prophylaxis to prevent future episodes of depression, also called maintenance treatment. This article describes the protocol for a randomised controlled trial (ANTLER: ANTidepressants to prevent reLapse in dEpRession) to investigate the clinical effectiveness and cost-effectiveness in UK primary care of continuing on long-term maintenance antidepressants compared with a placebo in preventing relapse of depression in those who have taken antidepressants for more than 9 months and who are currently well enough to consider stopping maintenance treatment. METHODS/DESIGN: The ANTLER trial is an individually randomised, double-blind, placebo-controlled trial in which participants are randomised to remain on active medication or to take an identical placebo after a tapering period of 2 months. Eligible participants are those who: are between the ages of 18 and 74 years; have had at least two episodes of depression; and have been taking antidepressants for 9 months or more and are currently taking citalopram 20 mg, sertraline 100 mg, fluoxetine 20 mg or mirtazapine 30 mg but are well enough to consider stopping their medication. The participants will be followed up at 6, 12, 26, 39 and 52 weeks. The primary outcome will be the time in weeks to the beginning of the first episode of depression after randomisation. This will be measured using a retrospective version of the Clinical Interview Schedule-Revised administered at 12, 26, 39 and 52 weeks. Secondary outcomes will include depressive and anxiety symptoms, adverse effects, withdrawal symptoms, emotional processing tasks, quality of life and the resources and costs used. We will also perform a cost-effectiveness analysis based on results of the trial. DISCUSSION: The ANTLER trial findings will inform primary care prescribing practice by providing a valid and generalisable estimate of the clinical effectiveness and cost-effectiveness of long-term maintenance treatment with antidepressants in UK primary care. TRIAL REGISTRATION: Controlled Trials ISRCTN Registry, ISRCTN15969819. Registered on 21 September 2015.
引用
- Duffy L, Bacon F, Clarke CS, et al. A randomised controlled trial assessing the use of citalopram, sertraline, fluoxetine and mirtazapine in preventing relapse in primary care patients who are taking long-term maintenance antidepressants (ANTLER: ANTidepressants to prevent reLapse in dEpRession): study protocol for a randomised controlled trial. Trials. 2019. PMID: 31159856. doi:10.1186/s13063-019-3390-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。